photo #9007476

As emails from us are notoriously diverted to bulk, spam, junk, or blacklisted and nkt delivered at all, I wanted to make a public post on updates with our drug testing venture as many of you hold interest. For the past 20 months, we’ve been laying groundwork.Not flashy groundwork. Not social media noise. Real groundwork.The longest days. Brutal schedules. Constant travel. Meetings that go nowhere until they suddenly do. Federal conversations that take months just to move an inch. Healthcare systems that require patience, proof, and discipline before they ever say yes.This kind of work doesn’t show up in headlines.But it compounds.And in the first 60 days of 2026 — especially in February — it has started to show.The largest healthcare network in Arizona is now the first purchaser of our 5-panel platform — a system many in this industry said was either impossible or unrealistic to execute at this level. The same people who said, “If someone could pull it off, it would become the model for detection and saving lives.”It’s no longer theoretical. We have done it. We now have the only 16-panel Urine drug testing cup that is FDA-CLEARED and CLIA-WAIVED that includes fentanyl detection on the Cup. At the federal level, I’ve now had my third meeting in six months with SAMHSA leadership.Let’s me be very clear here — SAMHSA cannot endorse any specific test or company. That’s federal policy and appropriate.But what they can do is educate.And SAMHSA crafted the idea for a national webinar specifically so I could educate their award recipients on emerging threats (nitazenes, medetomidine, etc.) and present the framework and the science behind why single panel and dilution-based testing creates detection gaps. SAMHSA is conducting the webinar. I will be the primary speaker to their award recipients (SAMHSA provides $2.8 billion for mental health activities and $4.2 billion for substance abuse treatment annually). SAMHSA is currently reviewing the first draft of the presentation (slides below) for public health alignment, accuracy, and against their no endorsement policy. That’s not an endorsement.That’s earned access.Last week, at the request of the Department of Veterans Affairs, we also submitted a formal proposal to bring this platform into the VA system. That request did not come from cold outreach. It came after sustained engagement and is currently being reviewed by whomever in the hierarchy approves their pricing and budget. We have a second meeting scheduled this month with Robert F. Kennedy Jr. after meeting with him last year. I am in regular contact with his team and you will now see they are active in substance abuse and just announced their STREETS initiative and have allocated $100,000,000.00 for lifesaving measures. Sara Carter has now been confirmed (finally after a 10 month wait) as Drug Czar and will soon roll out a comprehensive national strategy. When the Office of National Drug Control Policy releases its framework, we will launch our "Test Every Drug" campaign — similar in spirit to “Just Say No,” but built for the multi-substance, deadly reality we’re actually facing. SAMHSA has agreed to participate from an educational standpoint once ONDCP’s plan is public.And while all of this has been unfolding externally, we strengthened internally.We retained new corporate counsel built for SEC scrutiny, IPO-level compliance expectations, audit preparation, and navigating purported mergers and regulatory complexity. If you’re going to operate at national scale — especially in healthcare and government — governance cannot be an afterthought. It has to be ahead of the curve.It is. We are. They will also be issuing K1 statements this coming week. None of this happened overnight.Government timelines are slow. Healthcare adoption is deliberate. Federal engagement requires patience and repetition. It takes time for serious work to come to fruition.But when the groundwork is real, momentum doesn’t trickle in.It converges.The first 60 days of 2026 have made that clear.And February is just getting started.Thank you. — Jase